Carl Gordon is a founding General Partner of OrbiMed and Co-Head of Private Equity. Carl Gordon is active in both private equity and small-capitalization public equity investments.He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997.He was a Fellow at The Rockefeller University from 1993 to 1995. Carl Gordon received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology. His doctoral work involved studies of protein folding and assembly. He received a Bachelors degree from Harvard College.
| Organization Name | Title At Company | Start Date | End Date | |
|---|---|---|---|---|
Scribe Therapeutics
|
Board of Director | Jan 1, 2021 | — | Detail |
MBX Biosciences
|
Board Member | Jul 1, 2020 | — | Detail |
ORIC Pharmaceuticals
|
Board Member | — | — | Detail |
Arsanis
|
Board of Directors | — | — | Detail |
Good Start Genetics
|
Board Member | — | — | Detail |
Star Therapeutics
|
Board Member | — | — | Detail |